MR Imaging Features of Amyloid-Related Imaging Abnormalities

REFERENCES

1. 1.↵
   1. Black RS,
   2. Sperling RA,
   3. Safirstein B,
   4. et al

   . A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010;24:198–203

   CrossRefPubMed
2. 2.↵
   1. Sperling R,
   2. Bronen R,
   3. Greenberg S,
   4. et al

   . Three cases of apparent vasogenic edema (VE) from a phase 2 clinical trial of the gamma secretase inhibitor BMS-708163 in patients with mild-to-moderate AD. Alzheimers Dement 2011;7(suppl):S377
3. 3.↵
   1. Doody R

   . Results from independent analyses of the EXPEDITION (solanezumab) study data conducted by the Alzheimer's Disease Cooperative Study (ADCS). In: Proceedings of the Annual Meeting of The American Neurological Association, Boston, Massachusetts. October 7–9, 2012
4. 4.↵
   1. Ostrowitzki S,
   2. Deptula D,
   3. Thurfjell L,
   4. et al

   . Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012;69:198–207

   CrossRefPubMed
5. 5.↵
   1. Salloway S,
   2. Sperling R,
   3. Gilman S,
   4. et al

   . A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061–70

   CrossRef
6. 6.↵
   1. Sperling RA,
   2. Jack CR Jr.,
   3. Black SE,
   4. et al

   . Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011;7:367–85

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Sperling R,
   2. Salloway S,
   3. Brooks DJ,
   4. et al

   . Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012;11:241–49

   CrossRefPubMed
8. 8.↵
   1. Boche D,
   2. Zotova E,
   3. Weller RO,
   4. et al

   . Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008;131(pt 12):3299–310

   Abstract/FREE Full Text
9. 9.↵
   1. Eng JA,
   2. Frosch MP,
   3. Choi K,
   4. et al

   . Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 2004;55:250–56

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Scolding NJ,
    2. Joseph F,
    3. Kirby PA,
    4. et al

    . Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005;128(pt 3):500–15

    Abstract/FREE Full Text
11. 11.↵
    1. Carlson C,
    2. Estergard W,
    3. Oh J,
    4. et al

    . Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement 2011;7:396–401

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Oh U,
    2. Gupta R,
    3. Krakauer JW,
    4. et al

    . Reversible leukoencephalopathy associated with cerebral amyloid angiopathy. Neurology 2004;62:494–97

    CrossRef
13. 13.↵
    1. Kinnecom C,
    2. Lev MH,
    3. Wendell L,
    4. et al

    . Course of cerebral amyloid angiopathy-related inflammation. Neurology 2007;68:1411–16

    CrossRef
14. 14.↵
    1. Savoiardo M,
    2. Erbetta A,
    3. Storchi G,
    4. et al

    . Case 159: cerebral amyloid angiopathy-related inflammation. Radiology 2010;256:323–27

    CrossRefPubMed
15. 15.↵
    1. Sakaguchi H,
    2. Ueda A,
    3. Kosaka T,
    4. et al

    . Cerebral amyloid angiopathy-related inflammation presenting with steroid-responsive higher brain dysfunction: case report and review of the literature. J Neuroinflammation 2011;8:116

    CrossRefPubMed
16. 16.↵
    1. Rinne JO,
    2. Brooks DJ,
    3. Rossor MN,
    4. et al

    . 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363–72

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Weller RO,
    2. Subash M,
    3. Preston SD,
    4. et al

    . Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008;18:253–66

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Schroeter S,
    2. Khan K,
    3. Barbour R,
    4. et al

    . Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci 2008;28:6787–93

    Abstract/FREE Full Text
19. 19.↵
    1. Vinters HV

    . Cerebral amyloid angiopathy: a critical review. Stroke 1987;18:311–24

    FREE Full Text
20. 20.↵
    1. Filippi CG,
    2. Ulug AM,
    3. Lin D,
    4. et al

    . Hyperintense signal abnormality in subarachnoid spaces and basal cisterns on MR images of children anesthetized with propofol: new fluid-attenuated inversion recovery finding. AJNR Am J Neuroradiol. 2001;22:394–99

    Abstract/FREE Full Text
21. 21.↵
    1. Stuckey SL,
    2. Goh TD,
    3. Heffernan T,
    4. et al

    . Hyperintensity in the subarachnoid space on FLAIR MRI. AJR Am J Roentgenol 2007;189:913–21

    CrossRefPubMed